Apoptosis: Intrinsic and Extrinsic Pathways, Caspases, Morphology and Clinical Relevance

Learning outcomes

• Define apoptosis and distinguish it from necrosis and other regulated lytic pathways.
• Explain the intrinsic mitochondrial and extrinsic death-receptor pathways.
• Describe BCL-2 family control, mitochondrial outer-membrane permeabilisation, cytochrome c, apoptosome formation and caspase activation.
• Explain initiator versus executioner caspases and the role of inhibitor-of-apoptosis proteins.
• Recognise apoptotic morphology, apoptotic bodies, phosphatidylserine exposure and efferocytosis.
• List physiologic and pathologic examples and understand how cancer, autoimmunity, infection and drugs alter apoptosis.
• Interpret laboratory and histology findings and apply the concepts to emergency and clinical cases.

1. Definition and distinguishing features

Apoptosis is a tightly controlled form of cell death mediated by proteolytic caspases. It removes individual cells or small groups without spilling intracellular contents. The process requires enough ATP and cellular organisation to execute signalling, dismantling and phagocytic recognition.

Feature	Apoptosis	Necrosis
Cell size	Shrinks and becomes dense.	Swells and becomes pale or eosinophilic.
Membrane	Intact, with blebbing and apoptotic-body formation.	Permeability fails and membrane ruptures.
Nucleus	Chromatin condensation and orderly fragmentation.	Pyknosis, karyorrhexis, karyolysis and loss of architecture.
Cell contents	Packaged into membrane-bound bodies.	Leak into interstitium and circulation.
Inflammation	Usually absent or minimal.	Usually prominent.
Energy	Requires ATP and regulated signalling.	Severe energy failure predominates.
Typical scale	Single cells or small clusters.	Contiguous areas of tissue.

2. Physiologic roles

2.1 Development and morphogenesis

• Separates fingers and toes by removing interdigital tissue.
• Shapes the nervous system by deleting excess neurons and synapses.
• Removes transient embryonic structures such as Müllerian or Wolffian remnants.
• Controls organ size by balancing proliferation with death.

2.2 Homeostatic turnover

• Intestinal epithelial cells die at the villus tip and are replaced from crypt stem cells.
• Endometrial cells undergo hormone-withdrawal apoptosis during menstruation.
• Skin, liver and immune tissues remove aged or damaged cells without disrupting the barrier.
• Neutrophils undergo apoptosis at the end of an acute inflammatory response.

2.3 Immune regulation

Apoptosis deletes autoreactive lymphocytes during central tolerance, contracts an immune response after pathogen clearance and removes infected or tumour cells through cytotoxic lymphocytes. Failure of this balance can produce autoimmunity, immunodeficiency or cancer.

3. The central control system: BCL-2 family proteins

The intrinsic pathway is governed by the balance between pro-survival and pro-death BCL-2 family proteins at the mitochondrial outer membrane.

Group	Representative proteins	Function
Pro-survival	BCL-2, BCL-xL, MCL-1, A1.	Keep mitochondrial membranes intact and restrain BAX/BAK.
Multi-domain pro-apoptotic	BAX, BAK.	Oligomerise to form pores in the mitochondrial outer membrane.
BH3-only sensors	BIM, BID, BAD, PUMA, NOXA, BMF.	Sense growth-factor withdrawal, DNA damage, ER stress, toxins and cytokines; inhibit survival proteins or activate BAX/BAK.

Cell survival depends on growth factors, intact metabolism and anti-apoptotic proteins. DNA damage, hypoxia, loss of attachment or trophic signals increase BH3-only activity. When BAX/BAK-mediated permeabilisation exceeds the anti-apoptotic reserve, the point of no return for intrinsic apoptosis is reached.

4. Intrinsic (mitochondrial) apoptosis pathway

4.1 Triggers

• Irreparable DNA damage from radiation, cytotoxic drugs, ROS or replication stress.
• Growth-factor or hormone withdrawal.
• Severe ER stress and accumulation of misfolded proteins.
• Loss of cell-matrix attachment (anoikis).
• Some viral infections and intracellular toxins.

4.2 Molecular sequence

1. Stress activates BH3-only proteins and weakens BCL-2-mediated survival.
2. BAX and BAK oligomerise in the mitochondrial outer membrane.
3. Mitochondrial outer-membrane permeabilisation (MOMP) releases cytochrome c and other pro-death factors.
4. Cytochrome c binds APAF-1 and procaspase-9 in an ATP-dependent apoptosome.
5. Caspase-9 activates executioner caspases-3 and -7.
6. Executioner caspases cleave cytoskeletal proteins, nuclear lamins, DNA-repair proteins and endonuclease inhibitors.
7. The cell fragments into apoptotic bodies and exposes “eat-me” signals for efferocytosis.

4.3 Mitochondrial factors beyond cytochrome c

Smac/DIABLO and Omi/HtrA2 neutralise inhibitor-of-apoptosis proteins (IAPs). Apoptosis-inducing factor (AIF) can contribute to caspase-independent DNA damage in severe injury. The balance of these factors determines whether a stressed cell remains viable, executes apoptosis or progresses to necrosis when ATP becomes inadequate.

5. Extrinsic (death-receptor) apoptosis pathway

5.1 Death receptors and ligands

Death receptors are members of the TNF receptor superfamily and contain intracellular death domains.

Receptor	Ligand/source	Clinical role
Fas (CD95)	Fas ligand on activated T cells and other cells.	Deletion of immune cells; cytotoxic T-cell killing; autoimmune lymphoproliferation when defective.
TNFR1	TNF from macrophages and other inflammatory cells.	Can activate NF-κB survival signals, apoptosis or necroptosis depending on adaptor and caspase activity.
TRAIL receptors	TRAIL on immune cells.	Surveillance against infected and malignant cells.

5.2 Molecular sequence

1. Ligand binds a death receptor and causes receptor trimerisation.
2. FADD adaptor proteins attach to the receptor death domain.
3. Procaspase-8 and/or procaspase-10 are recruited into the death-inducing signalling complex (DISC).
4. Initiator caspase-8 becomes active and directly activates executioner caspases-3 and -7.
5. Caspase-8 can cleave BID to tBID, which engages the mitochondrial pathway and amplifies death.

5.3 Caspase-8 checkpoint

When caspase-8 activity is inhibited, TNF or toll-like receptor signalling may shift from apoptosis to necroptosis through RIPK1/RIPK3/MLKL. Thus the same external signal can produce quiet apoptosis or inflammatory lytic death depending on intracellular conditions.

6. Caspases: the execution machinery

Class	Examples	Role
Initiator caspases	Caspase-8, -9, -10, -2.	Activated on signalling platforms such as the DISC or apoptosome; activate executioner caspases.
Executioner caspases	Caspase-3, -6, -7.	Cleavage of structural and regulatory proteins; nuclear fragmentation and apoptotic-body formation.
Inflammatory caspases	Caspase-1, -4, -5, -11.	Inflammasome signalling, gasdermin cleavage and pyroptosis rather than classic apoptosis.

Executioner caspases cleave nuclear lamins, cytoskeletal proteins, focal-adhesion molecules and ICAD (the inhibitor of caspase-activated DNase). Activated CAD fragments DNA into nucleosomal units, producing the laddering pattern used in experimental assays.

7. Morphology of apoptosis

7.1 Light microscopy

• Cell shrinkage and increased eosinophilia.
• Dense, sharply condensed chromatin against the nuclear envelope.
• Fragmentation into round, membrane-bound apoptotic bodies.
• Rapid phagocytic clearance, so few dead cells may be visible.
• Minimal surrounding neutrophils or tissue destruction.

7.2 Electron microscopy

Electron microscopy shows cytoplasmic condensation, dense organelles, nuclear chromatin margination and fragmentation, intact organelle membranes and surface blebs. Unlike necrosis, the plasma membrane remains continuous until the apoptotic body is engulfed.

7.3 Apoptotic-body clearance

Phosphatidylserine flips from the inner to the outer leaflet of the plasma membrane. Complement fragments, calreticulin, altered glycosylation and “find-me” signals (such as ATP/UTP) help phagocytes locate the dying cell. Macrophages recognise “eat-me” signals through receptors such as TIM-4, BAI1, MerTK and integrins. Efferocytosis produces anti-inflammatory mediators and prevents secondary necrosis.

8. Physiologic and pathologic examples

Setting	Mechanism or trigger	Example
Hormone withdrawal	Loss of survival signals; BCL-2 balance shifts toward death.	Endometrial shedding; ovarian follicle atresia.
Immune contraction	Fas/FasL and cytokine withdrawal delete activated lymphocytes.	Resolution after an infection.
DNA damage	p53 induces PUMA/BAX and mitochondrial apoptosis.	Radiation or chemotherapy injury.
Viral infection	Direct viral stress or cytotoxic T-cell Fas/granzyme killing.	Viral hepatitis with apoptotic hepatocytes.
Protein misfolding	Persistent ER stress and CHOP/JNK signalling.	Neurodegenerative disease.
Duct obstruction	Loss of trophic signals and pressure injury.	Pancreatic or salivary gland atrophy.
Immune tolerance failure	Defective deletion of autoreactive lymphocytes.	Autoimmune lymphoproliferative syndrome.
Cancer	TP53 loss, BCL-2 overexpression or IAP activation prevents apoptosis.	Lymphoma, leukaemia and solid tumours.

9. Apoptosis in disease

9.1 Too little apoptosis

• Cancer: p53 mutation, BCL-2 overexpression, PI3K/AKT survival signalling and IAP activity allow abnormal cells to survive.
• Autoimmunity: failure to delete autoreactive lymphocytes or defective Fas signalling causes persistent immune activation.
• Viral persistence: some viruses inhibit caspases or BCL-2-like proteins to prolong infected-cell survival.

9.2 Too much apoptosis

• Neurodegeneration: chronic protein misfolding, mitochondrial damage and trophic-factor withdrawal kill neurons.
• Ischaemia-reperfusion: apoptotic and necrotic death coexist in the infarct border zone.
• Viral disease: immune-mediated apoptosis can cause substantial parenchymal loss.
• Bone marrow failure: excessive apoptosis of progenitors produces cytopenias.
• Involution/atrophy: loss of hormonal or mechanical stimulation removes cells from a tissue.

10. Drugs and therapeutic manipulation

Therapeutic strategy	Mechanism	Examples/clinical relevance
DNA-damaging therapy	Activates p53 and mitochondrial apoptosis in rapidly dividing cells.	Many cytotoxic chemotherapies and radiotherapy.
BCL-2 inhibition	Releases pro-apoptotic proteins from BCL-2 sequestration.	Venetoclax in selected haematologic malignancies.
Death-receptor agonism	Attempts to activate extrinsic apoptosis in tumour cells.	Investigational and selected immunotherapeutic approaches.
Caspase inhibition	Can reduce experimental tissue injury but may divert signalling toward necroptosis.	Mostly research; not routine emergency therapy.
Immune checkpoint therapy	Restores cytotoxic T-cell activity against malignant cells, leading to tumour-cell apoptosis.	PD-1/PD-L1 or CTLA-4 pathway inhibitors.

Anti-cancer drugs that trigger apoptosis can produce tumour lysis syndrome. Rapid destruction releases potassium, phosphate, nucleic acids and urate; monitor high-risk patients and treat metabolic complications promptly.

11. Laboratory and pathology assessment

11.1 Histology

• Look for isolated shrunken cells, condensed chromatin and apoptotic bodies.
• Absence of a prominent neutrophilic infiltrate supports apoptosis but does not prove it.
• In viral hepatitis, apoptotic hepatocytes may appear as eosinophilic Councilman bodies.

11.2 Special assays

Test	What it detects	Limitations
Cleaved caspase-3 immunohistochemistry	Executioner-caspase activation.	May miss early or caspase-independent death and depends on sampling.
TUNEL assay	DNA strand breaks.	Also positive in necrosis and some repair processes; not apoptosis-specific.
Annexin V	Externalised phosphatidylserine.	Also appears in late necrosis; flow-cytometry interpretation requires membrane-impermeant dyes.
DNA laddering	Internucleosomal fragmentation.	Mostly research; insensitive in small samples.
Caspase activity assays	Enzyme activation in tissue or cells.	Pathway-specific interpretation and timing are essential.

11.3 Bedside interpretation

Apoptosis usually does not release a distinctive routine blood biomarker. Organ-specific enzymes may rise only when apoptotic burden is large or when secondary necrosis occurs. Clinical diagnosis therefore relies on context, histology, molecular assays and exclusion of more destructive causes.

12. Apoptosis, secondary necrosis and inflammation

Rapid efferocytosis keeps apoptotic cells immunologically quiet. If macrophages are overwhelmed, if the tissue is hypoxic, or if phagocytic recognition is defective, apoptotic bodies lose membrane integrity and undergo secondary necrosis. DAMPs then escape and inflammation follows. This explains why a disease may begin with apoptosis but later resemble necrosis histologically and clinically.

13. Emergency and clinical applications

1. Do not treat “apoptosis” as a bedside diagnosis in isolation. Find the trigger: toxin, ischaemia, infection, immune disease, malignancy or drug effect.
2. Protect viable tissue: correct hypoxia, shock, glucose and temperature abnormalities; apoptosis in the border zone may be preventable if the underlying insult is reversed.
3. Recognise therapy-related apoptosis: monitor for tumour lysis after chemotherapy or targeted therapy.
4. Consider infection and immunity: cytotoxic lymphocyte apoptosis of infected cells can coexist with necrotic inflammation and sepsis.
5. Support failing organs: excess apoptosis may be part of multi-organ injury even when routine necrosis markers are modest.

14. Applied cases

Case 1: Chemotherapy and tumour lysis

A patient with a high-burden lymphoma receives cytotoxic treatment and develops weakness, oliguria and an irregular pulse. Tumour-cell apoptosis and lytic death release potassium and phosphate, while nucleic acids become urate. Check ECG, electrolytes, renal function and urate; treat tumour lysis syndrome according to local protocol and involve oncology/nephrology early.

Case 2: Viral hepatitis

Infected hepatocytes may undergo intrinsic apoptosis, while cytotoxic T cells trigger extrinsic death. Councilman bodies represent apoptotic hepatocytes. The clinical syndrome may still include inflammation and high aminotransferases because immune cells and secondary injury are present.

Case 3: Autoimmune lymphoproliferation

Defective Fas-mediated deletion allows activated and autoreactive lymphocytes to persist. The patient may develop chronic lymphadenopathy, splenomegaly and autoimmune cytopenias. The pathology illustrates how insufficient apoptosis causes disease even without primary necrosis.

15. High-yield comparison

Feature	Intrinsic apoptosis	Extrinsic apoptosis	Necrosis
Initiator	Mitochondrial stress, DNA damage, growth-factor withdrawal.	Death receptor ligand (Fas, TNF, TRAIL).	Severe injury, ischaemia, toxin, infection.
Platform	Apoptosome.	DISC.	No single obligatory platform.
Initiator caspase	Caspase-9.	Caspase-8/10.	Often not caspase-dependent.
Executioner	Caspase-3/7.	Caspase-3/7.	Proteases, phospholipases and lysosomal enzymes.
Membrane	Intact with blebs and apoptotic bodies.	Intact with blebs and apoptotic bodies.	Ruptures.
Inflammation	Minimal unless clearance fails.	Minimal unless clearance fails.	Usually prominent.

16. Quick self-test

1. What is the key structural difference between apoptosis and necrosis?
   Answer: Apoptosis preserves the plasma membrane while packaging contents into apoptotic bodies; necrosis ruptures the membrane and leaks contents.
2. Which proteins create mitochondrial outer-membrane pores?
   Answer: BAX and BAK.
3. What is the apoptosome made from?
   Answer: Cytochrome c, APAF-1 and procaspase-9 in an ATP-dependent complex.
4. Which caspase is the usual initiator of the extrinsic pathway?
   Answer: Caspase-8 (or caspase-10 in humans).
5. What signal marks an apoptotic cell for phagocytosis?
   Answer: Externalised phosphatidylserine, alongside other “eat-me” signals.
6. Why can apoptosis become inflammatory?
   Answer: Failure of efferocytosis allows apoptotic bodies to undergo secondary necrosis and release DAMPs.
7. Give one disease caused by too little apoptosis and one caused by too much.
   Answer: Cancer or autoimmunity from too little; neurodegeneration or marrow failure from too much.
8. Why can a caspase inhibitor worsen inflammation?
   Answer: Blocking caspase-8 can divert TNF-family signalling toward necroptosis, a lytic inflammatory pathway.

17. Take-home summary

Selected references

• NCBI Bookshelf: Cell Injury, Cell Death and Adaptations
• NCBI Bookshelf: Histology, Cell Death
• Mechanisms and Morphology of Cellular Injury, Adaptation, and Death
• Molecular mechanisms of regulated cell death
• NCBI Bookshelf: Tumor Lysis Syndrome

Educational note: This resource supports learning and clinical reasoning. Current local protocols, senior supervision and national guidelines take precedence in patient care.